Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy

Journal of Clinical Pharmacology

Volumn 44, Issue 10, 2004, Pages 1166-1172

  Heo, Young Seol ^a,b   Chang, Heung Moon ^a   Kim, Tae Won ^a   Ryu, Min Hee ^a   Ahn, Jin Hee ^a   Kim, Sung Bae ^a   Lee, Jung Shin ^a   Kim, Woo Kun ^a   Cho, Hye Kyung ^b   Kang, Yoon Koo ^a,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Capecitabine; Cisplatin; Docetaxel; Hand foot syndrome; Vinorelbine

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; NAVELBINE;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; ERYTHEMA; FEMALE; FOOT; HAND; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SYNDROME;

EID: 4444335026     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268321     Document Type: Article

References (23)

1. Baack BR, Burgdorf WHC. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24:457-461.
2. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002; 20:3-10.
3. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
4. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62:361-369.
5. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101:798-800.
6. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001;61: 2309-2326.
7. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
8. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
9. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
10. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4:1567-1571.
11. Kang YK, Kim TW, Chang HM, et al. Phase I-II study of docetaxel, capecitabine, and cisplatin as first-line chemotherapy in advanced gastric cancer [abstract 1319]. Proc Am Soc Clin Oncol. 2003;20.
12. Kim TW, Chang HM, Kang JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14:1115-1120.
13. Kim TW, Kang YK, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002;13:1893-1898.
14. Ahn JH, Kim SB, Lee JS, Kim WK. Phase II study of a combination of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: preliminary results [abstract 2030]. Proc Am Soc Clin Oncol. 2002;21.
15. Venturini M, Durando A, Garrone O, Colozza MA, Contu A, Stevani I, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer. 2003;97:1174-1180.
16. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol. 2002;20:2616-2623.
17. Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25:599-602.
18. Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC. Fixed erythrodysesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol. 2000;142:808-811.
19. Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxenes and antimetabolites: its use and limitations. Eur J Cancer. 2001;37:2310-2323.
20. Pronk LC, Vasey P, Sparreboom A, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83:22-29.
21. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998;82:965-969.
22. Gyorgy P, Eckardt R. Vitamin B6 and skin lesions in rats. Nature. 1939;144:512.
23. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology. 2002; 16(suppl 14):31-37.